E. Levitin, V. A. Oridoroga
Dec 1, 2003
Citations
0
Influential Citations
1
Citations
Journal
Pharmaceutical Chemistry Journal
Abstract
This study was aimed at the development of an experimental technology for the commercial synthesis of a parent substance for the new drug analben based on potassium 2,4-dichlorobenzoate (I). This salt is known to possess pronounced analgesic, antiinflammatory, antipyretic, and hepatoprotector properties [1, 2]. With respect to the therapeutic breadth, analben exceeds reference drugs such as analgin, indomethacin, and voltaren. It was suggested to use analben for relieving acute pain of various etiologies (myalgia, radiculitis, etc.) and for treating disorders accompanied by inflammatory processes (arthritis, rheumatism, etc.). The known method of obtaining potassium 2,4-dichlorobenzoate is based on the interaction of potassium carbonate with 2,4-dichlorobenzoic acid (II) in an aqueous or aqueous alcohol media [3]. It might seem that this simple neutralization reaction described by the equation